Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Vanguard Personalized Indexing Management LLC

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Vertex Pharmaceuticals by 7.6%, now owning 38,491 shares worth approximately $17.14 million.
• Analysts have adjusted their price targets for Vertex Pharmaceuticals, with Royal Bank of Canada lowering theirs from $430 to $405, while JPMorgan Chase raised theirs from $517 to $530.
• Insider activity shows Director Bruce I. Sachs purchased 5,000 shares for around $1.95 million, increasing his stake by 12.5%.

Vanguard Personalized Indexing Management LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 7.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,491 shares of the pharmaceutical company's stock after purchasing an additional 2,729 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Vertex Pharmaceuticals were worth $17,138,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Advisor OS LLC lifted its holdings in shares of Vertex Pharmaceuticals by 4.4% in the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company's stock valued at $263,000 after purchasing an additional 23 shares in the last quarter. Costello Asset Management INC raised its holdings in shares of Vertex Pharmaceuticals by 3.6% during the second quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company's stock worth $307,000 after acquiring an additional 24 shares in the last quarter. Avidian Wealth Enterprises LLC raised its holdings in shares of Vertex Pharmaceuticals by 2.1% during the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock worth $594,000 after acquiring an additional 25 shares in the last quarter. Strategic Blueprint LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.7% during the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company's stock worth $726,000 after acquiring an additional 25 shares in the last quarter. Finally, Newman Dignan & Sheerar Inc. raised its holdings in shares of Vertex Pharmaceuticals by 3.3% during the second quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company's stock worth $350,000 after acquiring an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on VRTX shares. Royal Bank Of Canada cut their price objective on Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating for the company in a report on Tuesday, August 5th. Raymond James Financial started coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a "market perform" rating for the company. Weiss Ratings reiterated a "hold (c+)" rating on shares of Vertex Pharmaceuticals in a report on Wednesday. HC Wainwright cut their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating for the company in a report on Tuesday, August 5th. Finally, JPMorgan Chase & Co. increased their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an "overweight" rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $494.38.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $407.79 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The stock's 50-day moving average is $393.91 and its two-hundred day moving average is $439.18. The firm has a market cap of $104.55 billion, a P/E ratio of 29.15 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same period last year, the company earned ($12.83) earnings per share. The business's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.